• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21592 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Guideline for the management of bipolar disorders in Catalonia]
2017     Andalusian Health Technology Assessment Area (AETSA) [Guideline for the elaboration of recommendations and appropriate use criteria in health technologies]
2016     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Guideline for the elaboration and adaptation of rapid health technology assessment reports]
2007     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Guided use of autologous chondrocyte implant: a five-year follow-up]
2015     Basque Office for Health Technology Assessment (OSTEBA) [Guide to evidence-based recommendations in the prevention and treatment of pressure ulcers in adults]
2014     Andalusian Health Technology Assessment Area (AETSA) [Guide to clinical practice of care in pregnancy and puerperium]
2017     Basque Office for Health Technology Assessment (OSTEBA) [Guide on Prader-Willi Syndrome. Guide to health personnel for the adequate knowledge and management of a rare disease called Prader-Willi Syndrome]
2016     Andalusian Health Technology Assessment Area (AETSA) [Guide for the preparation of evidence synthesis reports: medicines. Update]
2013     Andalusian Health Technology Assessment Area (AETSA) [Guide for the preparation of drug evaluation reports]
2013     Andalusian Health Technology Assessment Area (AETSA) [Guide for proper use of knee arthroplasty in patients with arthritis]
2013     Andalusian Health Technology Assessment Area (AETSA) [Guide for proper use of knee arthroplasty in patients with arthritis. Short version]
2013     Andalusian Health Technology Assessment Area (AETSA) [Guide for proper use of knee arthroplasty in patients with arthritis. Fast version]
2007     Andalusian Health Technology Assessment Area (AETSA) [Guide for decision-making on the introduction of genetic tests in the National Health System (GEN guide) Version 1]
2017     Basque Office for Health Technology Assessment (OSTEBA) [Guide for breastfeeding mother. Guide for women who wish to breastfeed or who breastfeed, as well as their partners and family]
2009     Basque Office for Health Technology Assessment (OSTEBA) [Group monitoring of psychotic patients in the public health network of the Basque Autonomous Community]
2011     The Netherlands Organisation for Health Research and Development (ZonMw) [Group medical appointments for neuromuscular patients]
2009     Finnish Office for Health Care Technology Assessment (Finohta) [Green laser treatment of hyperplasia of the prostate]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glycopyrronium bromide (sialorrhoea) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glycopyrronium (axillary hyperhidrosis) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glycerol phenylbutyrate (urea-cycle disorders) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glycerol phenylbutyrate (urea cycle disorders) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Glucocorticosteroid intravitreal implants in posterior retina diseases]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glucarpidase (toxic MTX plasma concentrations) - Assessment according to §35a SGB V (1), Sentence 11]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glofitamab (diffuse large B-cell lymphoma) – Assessment according to § 35a Social Code Book (SGB) V (1) Sentence 11]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Global postural re-education in spine diseases]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Global postural re-education (RPG®) in spine conditions]
2008     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glitazones in the treatment of diabetes mellitus type 2]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glinides in the treatment of diabetes mellitus type 2]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glecaprevir/pibrentasvir (chronic hepatitis C) - Benefit assessment according to § 35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glecaprevir/pibrentasvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glecaprevir/pibrentasvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glecaprevir/pibrentasvir (chronic hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V]
2010     Committee for New Health Technology Assessment (CNHTA) [Glaucoma mini shunt implant surgery]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glasdegib (acute myeloid leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2008     Committee for New Health Technology Assessment (CNHTA) [GLA gene, mutation[sequencing]]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Givosiran (acute hepatic porphyria) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2008     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ginkgo compounds in Alzheimer's disease]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Gilteritinib (AML) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2009     Committee for New Health Technology Assessment (CNHTA) [GFAP gene, mutation[sequencing]]
2014     Basque Office for Health Technology Assessment (OSTEBA) [Geographical mental health map: geographical variation in psychosis and association with environmental factors]
2009     Committee for New Health Technology Assessment (CNHTA) [Genotyping of MDM2 SNP309 polymorphism]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Genomic expression tests in patients with breast cancer: MammaPrint®, Oncotype DX® and Prosigna®]
2011     Basque Office for Health Technology Assessment (OSTEBA) [Genetics development plan in the Basque Country]
2002     Andalusian Health Technology Assessment Area (AETSA) [Genetic testing services for hereditary diseases in Spain: results from a survey - primary research]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Genetic testing in primary dystonia]
2013     Andalusian Health Technology Assessment Area (AETSA) [Genetic testing for predicting treatment response in major depressive disorders]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Genetic testing for lynch syndrome in colorectal cancer and family members]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Genetic sequencing panel for motor-sensory hereditary neuropathy diagnosis]
2010     Andalusian Health Technology Assessment Area (AETSA) [Genetic screening of colorrectal neoplasms through fecal DNA analysis]
2014     Andalusian Health Technology Assessment Area (AETSA) [Genetic diseases in Spain: map of genetic tests available in the national health system]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Genetic counselling in congenital anomalies in the autonomous community of the Basque Country]
2007     Basque Office for Health Technology Assessment (OSTEBA) [Genetic counselling in breast cancer and colon cancer]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [General ultrasound screening for developmental dysplasia of the hip at three months of age: an implementation study]
2008     The Swedish Council on Health Technology Assessment (SBU) [General childhood vaccination against HPV 16 and 18 aimed at preventing cervical cancer]
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Gene sequencing of tumours: clinical validity and utility of molecular profiles obtained by next-generation sequencing (NGS) technologies]
2010     Andalusian Health Technology Assessment Area (AETSA) [Gene expression test for breast cancer Oncotype]
2015     Haute Autorite de sante (HAS) [Gene amplification to detect herpes simplex virus (HSV) and varicella-zoster virus (VZV) genomes in cerebrospinal fluid in cases of encephalitis]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Gender-specific differences in drug effects. Exemplary analysis based on beta-adrenoceptor antagonists as cardiac therapy and antidepressants as psychotropic drugs]
2000     Andalusian Health Technology Assessment Area (AETSA) [Gender dysphoria: possible interventions and coverage in Andalusian Health System - systematic review, economic evaluation]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Gemtuzumab ozogamicin (acute myeloid leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2010     Institute for Clinical Effectiveness and Health Policy (IECS) [Gefitinib for the treatment of lung cancer]
2008     Committee for New Health Technology Assessment (CNHTA) [GBA gene, mutation[sequencing]]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Gated-SPECT in ischemic non-obstructive coronary artery disease (microvascular angina - INOCA)]
2008     Committee for New Health Technology Assessment (CNHTA) [Gastric cancer sentinel node excision]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Gamma Knife versus adapted linear accelerators: A comparison of two radiosurgical applications]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Galsulfase (Naglazyme) for the treatment of mucopolysaccharidosis type VI]
2010     Committee for New Health Technology Assessment (CNHTA) [GALK1 gene mutation analysis[sequencing]]
2010     Committee for New Health Technology Assessment (CNHTA) [GALE gene,mutation[sequencing]]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Galcanezumab (migraine) - Second Addendum to Commission A19-28]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Galcanezumab (migraine) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Galcanezumab (migraine) - Addendum to commission A19-28]
2019     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Gait speed as predictor of frailty]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Gait laboratory in patients with gait disorders]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Gadoxetic acid-enhanced magnetic resonance imaging to diagnose focal liver lesions]
2008     Committee for New Health Technology Assessment (CNHTA) [GAA gene, mutation[sequencing]]
2017     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Functioning and disability - an evidence map]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Fulvestrant for the treatment of locally advanced ormetastatic breast cancer]
2015     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Fully bioresorbable scaffolds for coronary artery disease: systematic review]
2015     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) [Fully bioresorbable drug-eluting coronary scaffolds: A review]
2001     Finnish Office for Health Care Technology Assessment (Finohta) [From traditional film-based radiology to digital imaging: a simplified model for costing radiology services in small and medium-sized radiology units]
1999     Finnish Office for Health Care Technology Assessment (Finohta) [From science to practice - systematic reviews in health care]
2003     The Netherlands Organisation for Health Research and Development (ZonMw) [From efficacy to effectiveness in cancer research]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fremanezumab (prophylaxis of migraine) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fremanezumab (migraine) - Addendum to Commission A19-44]
2005     Andalusian Health Technology Assessment Area (AETSA) [Framework for the assessment of genetic testing in the Andalusian public health system]
2021     Canary Health Service [Framework for relations between the Spanish Network of HTA agencies of the NHS with industry]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fracture sonography in children with suspected fracture of a long tubular bone of the upper extremities]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Fractional flow-reserve by intracoronary pressure guidewire in patients with acute coronary syndrome]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Fractional flow reserve in coronary artery]
2015     Haute Autorite de sante (HAS) [Fractional flow reserve (FFR) measurement during coronary angiography]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Fractional exhaled nitric oxide measurement in patients with asthma and chronic cough]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fostemsavir (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fostamatinib (chronic immune thrombocytopenia) - Benefit assessment according to §35a Social Code Book V]
2021     Canary Health Service [Foot reflexology]
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Food in diabetes]
2007     Health Council of the Netherlands Gezondheidsraad (GR) [Food allergy]
2007     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Follow-up visits from nurses after discharge from multidisciplinary pain centre - a health technology assessment]
2009     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Follow-up in gynaecological cancer patients - a health technology assessment]
2009     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Follow-Up for gynecological cancer]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Foetal growth retardation at term: induction of labour or not? A comparison of maternal and neonatal outcome, maternal quality of life and costs (DIGITAT). The Disproportionate Intrauterine Growth Intervention Trial At Term (DIGITAT)]